Navigation Links
Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
Date:5/12/2008

for our planned trials in a timely manner; our need for capital, which may not be available on a timely basis, or at all; risks associated with requirements for approvals by government agencies such as the FDA before products can be tested in clinical trials; the possibility that such government agency approvals will not be obtained in a timely manner or at all or will be conditioned in a manner that would impair our ability to advance development; risks associated with the requirement that a drug candidate be found safe and effective after extensive clinical trials; our dependence on suppliers, collaborative partners and other third parties and the prospects and timing for obtaining clinical supply materials; our ability to attract and retain key personnel; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at http://www.sedar.com.

Assumptions underlying our expectations regarding forward-looking statements or information contained in this press release include, among others, that immunology responses are a predictor of clinical benefit; that immunological findings in our first three cohorts will be consistent with findings from our fourth cohort and future clinical studies; that safety and tolerability findings in all four cohorts will be consistent with findings from future clinical studies; that results from future clinical trials will be consistent with our expectations; that we will raise enough capital, on reasonable terms and in a timely manner; that we will retain our key personnel; that we will obtain the necessary regulatory approvals related to HspE7 and Poly-ICLC in a timely manner; that sufficient HspE7 and Poly-ICLC will be available to conduct our planned clinical trials; that we will obtain timely approval from additional Investigational Review Boards; that the results from additional preclinical and clinical work, if any, will be consist
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
3. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
4. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... LOUIS , July 11, 2014 /PRNewswire/ ... device company, announced today the positive, cost-effective ... its innovative SPiNPerc™ procedure. The SPiNPerc endobronchial ... of a percutaneous approach to biopsy when ... Hospitals, patients and physicians experience positive financial ...
(Date:7/10/2014)... NEWPORT NEWS, Virginia , 11. ... führender Hersteller von Kameras für die ... Brust (MBI/BSGI), hat heute die CE-Zulassung ... Mit dem CE-Zeichen kann Dilon das ... seinen Vertriebsbereich auf den Großteil der ...
(Date:7/10/2014)... INC. (NYSE: RMD ) today announced that it ... 30, 2014 results on Thursday, July 31, 2014, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... Radiation Oncology Solutions announced that it has ... medical linear accelerators at the John Theurer ... N.J. (Logo: http://photos.prnewswire.com/prnh/20101028/NE90717LOGO) ... which Varian designed to treat a moving ...
... YORK, Nov. 8, 2010 Reportlinker.com announces ... available in its catalogue: ... platforms, key players, and early pipeline candidates ... Therapeutic vaccines promise a new ...
Cached Medicine Technology:D3 Radiation Oncology Solutions has Completed Collaborative Commissioning of Two Varian TrueBeam Medical Linear Accelerators at the John Theurer Cancer Center, Hackensack University Medical Center 2D3 Radiation Oncology Solutions has Completed Collaborative Commissioning of Two Varian TrueBeam Medical Linear Accelerators at the John Theurer Cancer Center, Hackensack University Medical Center 3Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 2Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 3Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 4Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 5Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 6Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 7Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 8Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 9
(Date:7/12/2014)... 12, 2014 Casinos in ... rising competition from international and online casinos. Revenue is ... the five years through 2014-15. Greater per capita gambling ... gaming services. Rises in discretionary income levels have also ... on non-essential items such as casino gambling services. Revenue ...
(Date:7/12/2014)... "The second toes cross over the big ... wear shoes," said an inventor from East Hartford, Conn. This ... from happening. , He then created a prototype of the ... second and big toes from overlapping. This avoids discomfort and ... and easy to use, it's ideal for people with foot ...
(Date:7/12/2014)... 12, 2014 Using and carrying around ... two inventors from Ashland, Va., decided that there needed ... inspired us to conceive of our design," he said. ... KIDNEY KOVER, which provides an inconspicuous way to use ... as well as promotes comfort and peace of mind. ...
(Date:7/12/2014)... Beverly Hills, CA (PRWEB) July 12, 2014 ... reason why are bodies can readily absorb the nutrients in ... into tiny particles that are small enough to be absorbed ... the DZ10 team, a lack of enzymes in regular food ... DZ10 is a product that was started by Michelle DelPresto, ...
(Date:7/12/2014)... Doylestown Hospital recently conducted an interview with Dr. ... Paddock tackles topics including main men's health concerns, ... than men, and testosterone replacement therapy, among others. In ... on Doylestown Hospital’s website, Dr. Brad Paddock says, “A ... you notice pain, bulging, or asymmetry in your lower ...
Breaking Medicine News(10 mins):Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2
... Multi-year contract provides IP VPN service to eight sites nationwide, - Triples ... legacy ... solution, ROCHESTER, N.Y., ... provider of managed voice and data,networking solutions for businesses, today announced a ...
... Wash. March 17, 2008 The International Neuroinformatics ... Science announced today that the INCF will contribute infrastructure ... Institutes Allen Brain AtlasMouse Brain. Publicly available for ... Brain AtlasMouse Brain is a Web-based, genome-wide map of ...
... discovered what chemical in the eye triggers the dormant ... cells, a stem-like cell that can generate new retinal ... Investigative Ophthalmology and Visual Science (IOVS), offers new hope ... as macular degeneration and retinitis pigmentosa. , This ...
... On The Go,Healthcare, Inc. (OTC Bulletin Board: ... software and systems integrator,announced today that after more ... has sold its Value Added Reseller (,VAR,),business unit ... Board: FLIP). The,terms of the sale, in the ...
... from North Carolina State University have shown that silencing ... harmful carcinogens in cured tobacco leaves. , The finding ... with reduced amounts of cancer-causing agents. , NC ... Dr. Ramsey Lewis, assistant professor of crop science, teamed ...
... Neuroethics, in March 2008. Appearing three times a year, it ... related issues in the sciences of the mind. Springer ... all articles during 2008 and 2009. , Neuroethics will be ... the neuroscience of ethics. The journal will be highly ...
Cached Medicine News:Health News:CooperVision Increases Network Performance While Reducing Costs With Time Warner Telecom's IP VPN 2Health News:CooperVision Increases Network Performance While Reducing Costs With Time Warner Telecom's IP VPN 3Health News:INCF and Allen Institute for Brain Science collaborate on Brain Atlas service improvement 2Health News:INCF and Allen Institute for Brain Science collaborate on Brain Atlas service improvement 3Health News:Scientists successfully awaken sleeping stem cells 2Health News:On The Go Healthcare Sells VAR Business to Wireless and Internet Space Development Leader FTS Group 2Health News:On The Go Healthcare Sells VAR Business to Wireless and Internet Space Development Leader FTS Group 3Health News:On The Go Healthcare Sells VAR Business to Wireless and Internet Space Development Leader FTS Group 4Health News:Gene 'knockout' floors tobacco carcinogen 2Health News:Springer to publish new journal focusing on ethical issues in neuroscience 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: